---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Co-prescribed/Concomitant therapies. Topics: Proposed use in combination with other antihypertensive drugs; Launch-HTN: background regimen of 2 to 5 prescribed antihypertensive medications; Launch-HTN: background drug classes and other medications at randomization, No. (%); Launch-HTN: prohibited concomitant drugs; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Proposed use in combination with other antihypertensive drugs

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.2.12-2"></a>

### Launch-HTN: background regimen of 2 to 5 prescribed antihypertensive medications

> “Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.”
> “Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-3"></a>

### Launch-HTN: background drug classes and other medications at randomization, No. (%)

| Medication | Lorundrostat 50 mg and then 100 mg (n = 270) | Lorundrostat 50 mg (n = 541) | Placebo (n = 272) |
| --- | --- | --- | --- |
| Taking 2 antihypertensive medications | “106 (39.3)” | “213 (39.4)” | “113 (41.5)” |
| Taking ≥3 antihypertensive medications | “164 (60.7)” | “328 (60.6)” | “159 (58.5)” |
| Thiazide or thiazide-like diuretic | “259 (95.9)” | “520 (96.1)” | “259 (95.2)” |
| ACE inhibitor or ARB | “237 (87.8)” | “467 (86.3)” | “225 (82.7)” |
| Calcium channel blocker | “140 (51.9)” | “278 (51.4)” | “135 (49.6)” |
| Glucagon-like peptide-1 receptor agonists | “13 (4.8)” | “30 (5.6)” | “9 (3.3)” |
| Sodium-glucose cotransporter 2 inhibitors | “14 (5.2)” | “21 (3.9)” | “13 (4.8)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-4"></a>

### Launch-HTN: prohibited concomitant drugs

> “The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.12-5"></a>

### Advance-HTN: standardized background regimen of an ARB and a diuretic, with or without a calcium channel blocker

> “Participants who met screening criteria had their existing hypertension medications discontinued and started on a standard regimen of an angiotensin II receptor blocker (ARB) and a diuretic, if previously on two medications, or a standard regimen of ARB, diuretic and calcium channel blocker if previously on three to five medications.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

> “In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-2.1.2.12-6"></a>

### Target-HTN: background therapy and excluded concomitant drugs

> “Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.”
> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA,”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.12-7"></a>

### Target-HTN: larger blood pressure reduction with a background thiazide diuretic, November 2022

> “A prespecified sub-analysis demonstrated that blood pressure reduction by MLS-101 was further enhanced in subjects whose background antihypertensive regimen included a thiazide diuretic:”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-2.1.2.12-8"></a>

### Explore-CKD: added to an ACE inhibitor or ARB and an SGLT2 inhibitor

> “This trial was designed to evaluate blood pressure reduction and safety of 25 mg once-daily lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor for the treatment of hypertension in participants with CKD with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 and albuminuria (UACR of 200-5,000 mg/g).”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

> “Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-2.1.2.12-9"></a>

### Transform-HTN: existing antihypertensive medications continued

> “These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications.”
> “Results were similar among participants taking two background antihypertensive medications and those taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
